Avanafil-d4

• UNSPSC Description:

  Avanafil-d4 (TA1790-d4) is deuterium-labeled Avanafil (HY-18252)[1].

• Target Antigen:

  Endogenous Metabolite; Isotope-Labeled Compounds; NO Synthase; Phosphodiesterase (PDE)

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Immunology/Inflammation;Metabolic Enzyme/Protease;Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Endocrinology

• Smiles:

  COC1=C(Cl)C=C(CNC2=C(C(NCC3=NC=CC=N3)=O)C=NC(N4[C@H](C([2H])([2H])O)CCC4([2H])[2H])=N2)C=C1

• Molecular Weight:

  487.98

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Smith K A, et al. Soil and environmental analysis[M]. Marcel Dekker Incorporated, 2000.|[3]Fan T W M, et al. Stable isotope-resolved metabolomics and applications for drug development[J]. Pharmacology & therapeutics, 2012, 133(3): 366-391.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2012598-68-2